Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-08-21

Study Completion Date

2030-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study Description:

Patients with mutations of the insulin receptor have diabetes that is challenging to control with conventional therapies, leading to early morbidity and mortality. We hypothesize that recombinant leptin (metreleptin) in these patients will improve glycemia control.

Objectives:

Primary Objective: To determine if 1 year of metreleptin will improve glycemia control in patients with genetic defects of the insulin receptor. Secondary Objectives: To determine mechanisms by which metreleptin improves glycemia.

Endpoints:

Primary Endpoint: Hemoglobin A1c.

Secondary Endpoints: fasting plasma glucose, fasting insulin/C-peptide, glucose/insulin/C-peptide area under the curve during oral glucose tolerance test.

Study Population:

20 male or female patients with mutations of the insulin receptor, age (Bullet)5 years, at the NIH Clinical Center.

Description of Sites/Facilities Enrolling Participants: Description of Study Intervention:

NIH Clinical Center

Open label study of metreleptin, 0.2 mg/kg/day (max dose 0.24 mg/kg/day).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Leptin to Treat Lipodystrophy

NCT00025883

Lipodystrophy

COMPLETED PHASE2

Leptin to Treat Severe Insulin Resistance - Pilot Study

NCT00027456

Syndrome

COMPLETED PHASE2

Effects of Human Leptin Replacement

NCT00657605

Obesity Metabolic Syndrome Diabetes

COMPLETED PHASE2

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

NCT02262832

Lipodystrophy Diabetes Hyperlipidemia

ACTIVE_NOT_RECRUITING PHASE3

Effects of Leptin Replacement in Children

NCT00659828

Obesity Metabolic Syndrome Diabetes

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Description:

Patients with mutations of the insulin receptor have diabetes that is challenging to control with conventional therapies, leading to early morbidity and mortality. We hypothesize that recombinant leptin (metreleptin) in these patients will improve glycemia control.

Objectives:

Primary Objective: To determine if 1 year of metreleptin will improve glycemia control in patients with genetic defects of the insulin receptor. Secondary Objectives: To determine mechanisms by which metreleptin improves glycemia.

Endpoints:

Primary Endpoint: Hemoglobin A1c.

Secondary Endpoints: fasting plasma glucose, fasting insulin/C-peptide, glucose/insulin/C-peptide area under the curve during oral glucose tolerance test.

Study Population:

20 male or female patients with mutations of the insulin receptor, age (Bullet)5 years, at the NIH Clinical Center.

Description of Sites/Facilities Enrolling Participants: Description of Study Intervention:

NIH Clinical Center

Open label study of metreleptin, 0.2 mg/kg/day (max dose 0.24 mg/kg/day).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Leptin Treatment

300 mg of study drug administered via subcutaneous (SC) injections.

Group Type EXPERIMENTAL

Metreleptin

Intervention Type DRUG

Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metreleptin

Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of signed and dated informed consent form
* Male or female, aged \> 5 years
* Clinically significant, severe insulin resistance caused by a known or suspected defect in the insulin receptor
* Presence of at least one of the following metabolic abnormalities:

* Fasting insulin \>30 micro U/ml, or
* Presence of diabetes as defined by the 2006 American Diabetes Association (ADA) criteria:

* Fasting plasma glucose \>= 126 mg/dL
* 2 hour plasma glucose \>= 200 mg/dL following a 75 gram (1.75g/kg if less than 40kg) oral glucose load, or
* Diabetic symptoms with a random plasma glucose \>= 200 mg/dL

Exclusion Criteria

* Pregnant at time of enrollment, women in their reproductive years who do not use an effective method of birth control, and women currently nursing or lactating within 6 weeks of having completed nursing.
* Known infectious liver disease
* Known HIV infection
* Current alcohol or substance abuse
* Active tuberculosis
* Use of anorexigenic drugs
* Other conditions which in the opinion of the clinical investigators would impede completion of the study.
* Subjects who have a known hypersensitivity to E. Coli derived proteins.

Minimum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No